Psychedelic drugs may reduce criminal behavior

Illicit substances may be effective interventions to crime

October 23, 2017

Science Daily/University of British Columbia Okanagan campus

Newly published research suggests that common psychedelic drugs -- such as magic mushrooms, LSD and mescaline (a substance derived from the peyote cactus) -- may reduce criminal offences.

The new study, co-authored by UBC Okanagan's Associate Professor of Psychology Zach Walsh, found that psychedelic drugs are associated with a decreased likelihood of antisocial criminal behaviour.

"These findings add to a growing body of research suggesting that use of classic psychedelics may have positive effects for reducing antisocial behaviour," said Walsh, a p. "They certainly highlight the need for further research into the potentially beneficial effects of these stigmatized substances for both individual and public health."

Lead author, University of Alabama Assoc. Prof. Peter Hendricks, used data obtained by the National Survey on Drug Use and Health, which is administered by the U.S. Department of Health and Human Services, to explore the connection between the use of classic psychedelic substances and criminal behaviour among more than 480,000 American adult respondents from the past 13 years.

Key findings of the study are that respondents who have used psychedelic drugs had 27 per cent decreased odds of larceny or theft, and 22 per cent decreased odds of arrest for a violent crime in the past year. At the same time, lifetime use of other illicit substances was generally associated with increased odds of criminal behaviour.

Hendricks says that psilocybin and related compounds could revolutionize the mental health field.

"The development of innovative and effective interventions to prevent criminal behaviour is an obvious priority," Hendricks adds. "Our findings suggest the protective effects of classic psychedelic use are attributable to genuine reductions in antisocial behaviour rather than reflecting improved evasion of arrest. Simply put, the positive effects associated with classic psychedelic use appear to be reliable. Given the costs of criminal behaviour, the potential represented by this treatment paradigm is significant."

Walsh points out that research on the benefits of psychedelic drugs started decades ago, primarily to treat mental illness. However, it was stopped due to the reclassification of the drugs to controlled substances in the mid-1970s. Recent years have seen a resurgence of interest in psychedelic medicine.

"More research is needed to figure out what factors underlie these effects," Walsh says. "But the experiences of unity, positivity and transcendence that characterize the psychedelic experience may have lasting benefits that translate into real-world consequences."

The research was recently published by the Journal of Psychopharmacology.

https://www.sciencedaily.com/releases/2017/10/171023101753.htm

Classic psychedelic use protective with regard to psychological distress and suicidality

January 21, 2015

Science Daily/SAGE Publications

Classic psychedelics, such as LSD, psilocybin mushrooms and mescaline, previously have been shown to occasion lasting improvements in mental health. But researchers led by University of Alabama at Birmingham School of Public Health investigators wanted to advance the existing research and determine whether classic psychedelics might be protective with regard to suicidal thoughts and behaviors.

Approximately 30,000 lives in the United States are claimed by suicide every year, and more than 90 percent of victims have been diagnosed with mental illness, according to the National Alliance on Mental Illness.

Using data from more than 190,000 respondents of the National Survey on Drug Use and Health from 2008-2012, the researchers found that those who reported ever having used a classic psychedelic drug in their lifetime had a decreased likelihood of psychological distress in the past month, and decreased suicidal thinking, planning and attempts in the past year.

"Despite advances in mental health treatments, suicide rates generally have not declined in the past 60 years. Novel and potentially more effective interventions need to be explored," said Peter S. Hendricks, Ph.D., assistant professor in the Department of Health Behavior and lead study author. "This study sets the stage for future research to test the efficacy of classic psychedelics in addressing suicidality as well as pathologies associated with increased suicide risk (e.g., affective disturbance, addiction and impulsive-aggressive personality traits)."

Hendricks says the take-home message from this study is that classic psychedelics may hold great promise in the prevention of suicide and evaluating the therapeutic effectiveness of classic psychedelics should be a priority for future research.

https://www.sciencedaily.com/releases/2015/01/150121093544.htm

Mechanism of Hallucinogens' Effects Discovered

February 2, 2007

Science Daily/Cell Press

The brain mechanism underlying the mind-bending effects of hallucinogens such as LSD, mescaline, and psilocybin has been discovered by neuroscientists. They said their discoveries not only shed light on the longtime mystery of how hallucinogens work, but that the findings also offer a pathway to understanding the function of drugs used to treat neuropsychiatric disorders, which are now being used largely without an understanding of their fundamental mechanism.

Stuart Sealfon, Jay Gingrich, and colleagues published their findings in the February 1, 2007 issue of the journal Neuron, published by Cell Press.

Researchers have long known that hallucinogens activate specific receptors in the brain, called 5-HT2A receptors (2ARs), that are normally triggered by the neurotransmitter serotonin. Neurotransmitters are chemicals that one brain cell launches at receptors on another to trigger a nerve impulse in the receiving cell. However, a fundamental mystery has been why other compounds that activate the same receptors are not hallucinogenic.

In their studies, the researchers compared the differences between the effects of LSD and a nonhallucinogenic chemical that also activates 2AR receptors on the mouse neural machinery. Since the animals could not report the kinds of perception-altering effects that humans experience on hallucinogens, the researchers determined hallucinogenic properties by measuring a head twitch response the mice characteristically showed when under hallucinogens but not when under nonhallucinogens.

The scientists concentrated their studies on the cortex of the brain, which earlier studies had shown to be the center for action of the hallucinogens. Their analysis revealed that LSD produced genetic, electrophysiological, and internal cellular signaling responses that were distinctively different from those induced by a nonhallucinogenic compound.

They also explored whether 2ARs were central to the hallucinogenic effect of LSD by producing mice lacking the receptors, but in which receptor activity could be selectively restored in the cortex. The researchers found that mice without functioning receptors showed no hallucinogenic response to LSD, but restoring the receptors rendered LSD hallucinogenic in the animals.

The researchers wrote that "These studies identify the long-elusive neural and signaling mechanisms responsible for the unique effects of hallucinogens."

They also concluded that "The strategy we developed to elucidate [hallucinogen] action should be applicable to [central nervous system]-active compounds, with therapeutic potential in other disorders. Thus, our findings may advance the understanding of neuropsychiatric disorders that have specific pharmacological treatments whose mechanisms of action are not fully understood."

https://www.sciencedaily.com/releases/2007/01/070131135536.htm